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Abstract
Background: Angiogenesis is a common finding in chronic inflammatory diseases; however, its role in multiple
sclerosis (MS) is unclear. Central nervous system lesions from both MS and experimental autoimmune
encephalomyelitis (EAE), the animal model of MS, contain T cells, macrophages and activated glia, which can
produce pro-angiogenic factors. Previous EAE studies have demonstrated an increase in blood vessels, but
differences between the different phases of disease have not been reported. Therefore we examined angiogenic
promoting factors in MS and EAE lesions to determine if there were changes in blood vessel density at different
stages of EAE.
Methods: In this series of experiments we used a combination of vascular casting, VEGF ELISA and
immunohistochemistry to examine angiogenesis in experimental autoimmune encephalomyelitis (EAE). Using
immunohistochemistry we also examined chronic active MS lesions for angiogenic factors.
Results: Vascular casting and histological examination of the spinal cord and brain of rats with EAE demonstrated
that the density of patent blood vessels increased in the lumbar spinal cord during the relapse phase of the
disease (p < 0.05). We found an increased expression of VEGF by inflammatory cells and a decrease in the recently
described angiogenesis inhibitor meteorin. Examination of chronic active human MS tissues demonstrated glial
expression of VEGF and glial and blood vessel expression of the pro-angiogenic receptor VEGFR2. There was a
decreased expression of VEGFR1 in the lesions compared to normal white matter.
Conclusions: These findings reveal that angiogenesis is intimately involved in the progression of EAE and may
have a role in MS.
Background
Multiple sclerosis (MS) is a putative autoimmune dis-
ease of the central nervous system (CNS) and is one of
the most common neurological diseases of young adults
[1,2]. The exact cause of MS is unclear but appears to
be a complex interaction of genetic, environmental and
perhaps infectious causes [3,4]. It is characterized by
multifocal inflammatory lesions in the white matter
composed of lymphocytes, macrophages and activated
glia, that result in demyelination and axonal damage [5].
Most MS patients present with bouts of disease activity
(relapses) separated by periods of low disease activity
(remission). Over time accumulating damage results in
irreversible neurological impairment.
Besides the well characterized inflammatory infiltrate,
disturbances in the blood brain barrier (BBB) occur in
both MS and the animal model, experimental autoim-
mune encephalomyelitis (EAE) [6-8]. The BBB becomes
permeable to plasma proteins such as IgG, including
antibodies specific for myelin, which may promote
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ging (MRI) with gadolinium enhancement, these distur-
bances can be seen and quantified in MS patients
[11,12]. The appearance of perfusion deficits, detected
by MRI, has been shown to precede overt BBB break-
down [13]. However, the role of the blood vessels in
initiation, propagation and resolution of MS plaque for-
mation is still unclear.
Angiogenesis is a prominent feature of several CNS
diseases including brain tumors, epilepsy and stroke
[6,14-16]. Evidence is accumulating that angiogenesis
may have a role in the pathophysiology of MS and EAE,
similar to that seen in chronic inflammatory diseases of
peripheral organs [17]. In EAE, histological examination
has demonstrated an increased density of blood vessels
in areas of inflammation [18,19]. Vascular endothelial
growth factor (VEGF) is also increased at inflammatory
sites during EAE and MS and infusion of VEGF worsens
clinical scores during EAE [20]. Indeed an injection of
VEGF alone into the CNS of naive rats can induce
inflammation and angiogenesis [21]. There is also an
increase in serum VEGF in MS patients in relapse com-
pared to healthy controls or MS patients in remission
[22]. A recent paper by Holley and colleagues demon-
strated an increase in blood vessel density in MS lesions
compared to normal controls [23] and increased prolif-
eration of endothelial cells within these blood vessels.
Together these data suggest that angiogenesis is occur-
ring in EAE and MS.
The current experiments were performed to conclu-
sively demonstrate angiogenesis during different disease
phases of EAE, using vascular casting and histological
techniques. To examine autoimmune induced neuroin-
flammation, we used the spinal cord homogenate
induced EAE model in Lewis rats [24]. This model exhi-
bits acute monophasic disease and spinal cord inflam-
mation with subsequent relapse. This enabled us to
analyze early acute (day 9-15) and relapse (day 21-27)
phases of this disease. Furthermore, we examined MS
lesions for changes in angiogenic factors, which may be
responsible for driving the increased angiogenesis.
Methods
Induction and assessment of EAE
EAE is induced in female Lewis rats by guinea pig
spinal cord homogenate plus complete Freund’sa d j u -
vant. Clinical symptoms present with an acute phase
beginning at day 9 post immunization. This is followed
by a remission period from days 15 to 20 and then a
weaker relapse compared to the acute phase beginning
at day 21 (average clinical score of 1 vs. 2.5 in the
acute phase). The relapse is completed by day 28 in
the majority of rats, with complete recovery at that
time. 6-8 week old female Lewis rats (Harlan B.V.,
Horst, The Netherlands) were injected in the hind
paws with 0.1 ml of an emulsion containing 25 mg of
guinea pig spinal cord in complete Freund’s adjuvant.
Clinical grades of EAE were assessed using a clinical
scale from 0 to 3. 0, normal, 1, loss of tail tonicity, 2,
weakness of one or both hind legs, or mild ataxia and
3, severe ataxia or paralysis accompanied by urinary
incontinence. In the current set of experiments 84% of
the immunized rats achieved a relapse (defined as at
least 2 consecutive days of a score equal to or greater
than 1).
All animal experiments were approved by and per-
formed in accordance to Novartis and local Swiss regu-
latory authorities.
Vascular corrosion casts and quantification
Deeply anesthetized rats were thoracectomized and per-
fused through the left ventricle of the heart with rinsing
solution (NaCl 0.9% with 250,000 U/l heparin at 35°C)
at a controlled pressure of 120 mm Hg for 5 minutes at
a rate of 20 ml/min. The right atrium was punctured to
provide outflow. This was followed by a solution of 2%
paraformaldehyde at 35°C, followed by up to 30 ml of
polyurethane resin (PUII4; Vasqtec, Zürich, Switzerland)
at the same rate. After 48 h, the resin-filled brain and
spinal cord were excised from the animal and the soft
tissue was removed by incubation with 7.5% KOH for
24 hr at 50°C. The casts were then thoroughly cleaned
and stored in distilled water before drying by
lyophilization.
Micro computer tomography measurements were per-
formed with a desk-top MicroCT (μCT40, SCANCO
Medical AG Bassersdorf, Switzerland). A voxel size of 8
μm in all three spatial dimensions was used. For each
vascular cast, thoracic and lumbar slices were evaluated,
covering a total of 20 mm. The determination of blood
vessel size was performed with IPL software (SCANCO).
An outer contour was produced automatically slice-by-
slice, following a rough contour that had been drawn by
hand in the starting slice. The region of interest (ROI)
was defined within the contour. The grey-value images
were segmented using fixed threshold to extract the
blood vessels (threshold 1.5% of maximal grey-scale
value which corresponds to a linear attenuation coeffi-
c i e n to f0 . 1 2c m
-1). The blood vessels were evaluated
using the direct distance transformation method [25] to
calculate their thickness.
Histology
Deeply anesthetized rats were perfused with PBS fol-
lowed by 4% paraformaldyde. Spinal cord and brain tis-
sues were removed and postfixed in 4% paraformaldyde
for 24 hours, followed by embedding in paraffin. Alter-
natively, following PBS perfusion, tissue was placed in
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isopentane. Areas of the PBS perfused spinal cord were
snap frozen for VEGF ELISA and stored at -80°C until
required.
Two or three separate areas of the cervical, thoracic
and lumbar area were examined from each rat. Sections
from frozen (10 μm) and paraffin (7 μm) embedded tis-
sues were mounted on slides and immunohistochemistry
or histochemical staining was performed.
Paraffin sections were dewaxed, hydrated and antigen
retrieval performed by heating sections at 98°C in citrate
buffer pH6.0. Frozen sections were fixed in acetone for
10 minutes at room temperature. Immunohistochemis-
try was performed as previously reported [26]. A list of
the primary antibodies and sources can be found in
Table 1.
Myelin was visualized by immersing slides in solo-
chrome cyanine RS (0.2%) for 10 minutes, washing in
tap water for 5 minutes and differentiating in iron alum
(10%) until the white and grey matter could be
differentiated.
Frozen human control white matter and white matter
containing chronic active lesion was obtained from the
Netherlands Brain Bank (see Table 2 for subject details).
Cryosections (10 μm) were thawed onto slides, dried for
30 minutes and stored at -80°C until required. Sections
were fixed in acetone for 5 minutes, endogenous peroxi-
dases quenched using 0.3% hydrogen peroxide in PBS
for 15 minutes and blocked in 10% normal human AB
serum for 30 minutes. The diluted primary antibody
was added for 60 minutes and visualized with the Envi-
sion biotin free kit (DakoCytomation, Glostrup, DK).
Lesions were confirmed to be chronic active by an area
of well demarcated demyelination surrounded by HLA+
macrophages and gliosis.
Normal rabbit or mouse IgG was used as a negative
control and found to be negative in all cases.
Quantification of histology
S o l o c h r o m e ,r a tI g G ,V E G F ,V E G F R 1 ,V E G F R 2 ,T i e - 2 ,
angiopoientin-1 and meteorin stained sections were
examined and the staining pattern determined. In many
instances two different antibodies were used to stain the
Table 1 Antibodies used for immunohistochemistry
Primary Antibody Source Isotype Species Reactivity* Clone or Reference Dilution Supplier
Angiopoietin-1 Mouse monoclonal IgG1 h, m, r F-1 4 μg/ml Santa Cruz Biotechnology, Santa Cruz, CA
Angiopoietin-1 Rabbit polyclonal IgG h, m, r Ab65835 2 μg/ml Abcam, Oxford, UK
GFAP Rabbit polyclonal IgG h, m, r G560A 1 μg/ml Promega, Madison, WA
Meteorin Rabbit polyclonal IgG h, m Ab56129 2 μg/ml Abcam
Meteorin Goat polyclonal IgG m AF3475 6 μg/ml R&D Systems, Abington, UK
Tie-2 Rabbit polyclonal IgG h, m, r Sc-9026 2 μg/ml Santa Cruz
VEGF Rabbit polyclonal IgG h, m, r sc-152 1 μg/ml Santa Cruz
VEGF Mouse monoclonal IgG1 h, m, r VG-1 3 μg/ml Abcam
VEGFR1 (Flt-1) Rabbit polyclonal IgG h Sc-74007 2 μg/ml Santa Cruz
VEGFR1 Rabbit polyclonal IgG h, m, r Ab2350 1 μg/ml Abcam
VEGFR2 (Flk-1) Rabbit polyclonal IgG h, m, r Ab2349 3 μg/ml Abcam
VEGFR2 Rabbit polyclonal IgG h, m, r Sc-504 2 μg/ml Santa Cruz
Collagen IV Rabbit polyclonal IgG r, m Ab19808 2 μg/ml Abcam
CD31 Rabbit polyclonal IgG h, m Ab78364 2 μg/ml Abcam
* h = human, m = mouse, r = rat
Table 2 Subject information for CNS tissue used in
immunohistochemistry
Case number sex age Post-mortem
delay (h)
Cause of death
MS1 F 41 8.25 natural causes
MS2 F 50 7.45 euthanasia
MS3 F 53 10.45 euthanasia
MS4 F 78 11.10 cerebral vascular
accident
MS5 M 43 8.30 pneumonia
MS6 M 53 5.30 respiratory
insufficiency
MS7 M 56 8.0 pneumonia
MS8 F 66 8.30 euthanasia
MS9 F 66 6.0 unknown
MS10 F 44 11.10 CVA relapse
Average ± SD 55 ± 11.9 8.4 ± 2
C1 F 68 5.45 euthanasia
(cancer)
C2 F 78 4.15 cerebral vascular
accident
C3 M 48 5.30 euthanasia
C4 M 53 14.25 heart failure
C5 M 56 9.15 myocardial infarct
Average ± SD 60.6 ± 12 7.7 ± 4
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different intensities, they recognized the same cells and/
or structures.
For human tissue the staining pattern for each protein
of interest was examined in the center, active rim and
surrounding normal appearing white matter in the MS
subjects (n = 12 lesions from 10 separate individuals).
This was compared to white matter from normal con-
trol subjects (n = 5). Whenever possible, 2 different
antibodies were used to confirm the staining pattern for
each antigen.
For blood vessel density, rat spinal cord tissue sections
stained for CD31 and collagen IV were examined. Using
a 40× objective, the number of blood vessels in the grey
matter (dorsal and ventral horns) and white matter (dor-
sal, lateral and ventral) were counted in each field. The
resulting 4 values for the grey and white matter were
averaged for each section. For each rat 2-5 separate
areas of the cervical, thoracic and lumbar spinal cord
were counted and an average calculated for each rat.
The spinal cord segments were identified by counting
the vertebrae during the tissue collection.
ELISA
The spinal cord was removed from PBS perfused rats,
separated into lumbar, thoracic and cervical areas, and
snap frozen in liquid nitrogen. Tissue homogenates
were made in PBS containing protease inhibitors, the
supernatant collected after centrifugation and stored at
-80°C until required. A specific rat VEGF ELISA kit
(R&D systems Abington, UK) was used to measure
VEGF levels.
Statistical analysis
An unpaired Student’s T-test was carried out to deter-
mine significance (GraphPad Prism version 4.00 for
Windows (GraphPad Software, San Diego California
USA). A value of p < 0.05 was considered significant.
Results
Blood vessel density increases during EAE
To investigate whether angiogenesis is present during
EAE, vascular casting was performed during the acute
(day 14) and relapse (day 27) phase of disease and com-
p a r e dt ot h o s eo b t a i n e df r o mn a i v er a t s .V i s u a li n s p e c -
tion of the casts showed an increase in blood vessels
during the relapse phase but not during the acute period
of disease (Figure 1). These new blood vessels appear to
be more torturous, with increased size, dilations and
curvatures in EAE rats compared to those found in
n a i v er a t s .T h eg r e ym a t t e ri sl o c a t e di nt h ec e n t e ro f
the cast and in healthy rats it is known that this area
contains a greater number of blood vessels [27]. By
visual inspection during EAE relapse, the increase in the
number of blood vessels in the grey matter appeared to
be greater than in the peripheral white matter, though
the white matter also had an increase in blood vessel
density. In this Lewis rat EAE model, inflammation is
found in both the grey and white matter due to immu-
nization with spinal cord homogenate. In addition, we
constantly observe an inflammatory gradient with the
lumbar region being more severely affected than the
thoracic and cervical regions in turn. This is due to the
fact that this model exhibits an ascending spinal cord
paralysis (data not shown). A difference in edema and
resultant swelling in the different regions therefore will
also impact on blood vessel counts.
To quantify the vascular casts, μCT was performed.
Confirming the visual examination, there was a signifi-
cant increase in blood vessel numbers in the lumbar
region of the spinal cord but not the thoracic spinal
cord (compare Figure 1D and 1E). The increase in
blood vessel numbers was most prominent in the small
diameter blood vessels (24 μM in diameter) but there
was an increased number in all diameters including
those over 0.1 mm.
Inflammation induced vasodilatation of small blood
vessels may allow better perfusion by the casting mate-
rial, thus erroneously showing an apparent increase in
vessel density. To determine whether this was the case,
a separate experiment was performed and histology was
used to quantify the number of blood vessels in the cer-
vical, thoracic and lumbar spinal cord of naive rats and
during the relapse phase of EAE (day 25). Immunohisto-
chemistry using antibodies to CD31 and collagen IV was
used to label blood vessels and counting was performed
on spinal cord white and grey matter. Collagen IV stain-
ing demonstrated a significant increase in blood vessel
density during the relapse phase in the grey (p < 0.01)
and white (p < 0.001) matter of the lumbar spinal cord
and in the thoracic white and grey matter (p < 0.05) as
compared to naive rats (Table 3). To confirm these
data, CD31 expressing blood vessels were counted.
These results were similar to those found for collagen
IV (Table 3). Similar to previous results we found that
CD31 staining was present in a more diffuse pattern on
endothelium in the inflamed CNS on some blood vessels
(Figure 2) [28] and even disappeared on other blood
vessels as noted by Tham and colleagues [29].
Blood vessel density was higher in the grey matter
than in the white matter, similar to that seen in the vas-
cular casting. However, unlike the vascular casting, his-
tological examination also demonstrated an increase in
vessel density within the thoracic spinal cord. An expla-
nation for this discrepancy is that vascular casting
depends on the blood vessel being patent. Histological
examination will detect all blood vessels including those
that are newly formed and not perfusable. Nevertheless,
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blood vessel density during EAE.
We then investigated if the blood vessel density chan-
ged during the different phases of EAE. Tissue was har-
vested from rats at different times after immunization
and blood vessels were quantified using collagen IV
staining. The number of blood vessels increased during
the relapse phase in the grey (p < 0.01) and white (p <
0.001) matter of the lumbar spinal cord and in the thor-
acic white matter (p < 0.05) as compared to naive rats
(Figure 3). There was a slight, but insignificant increase
at day 16 in the lumbar spinal cord grey matter, sug-
gesting that at this phase, blood vessel numbers began
to increase. We did not examine the tissues for CD31 as
this marker was reduced on the blood vessels of some
EAE animals which made counting more difficult.
Angiogenesis mediators are modulated during EAE
VEGF has been shown to be expressed in MS [30] and
is a potent inducer of angiogenesis in the brain, there-
fore we determined whether this pro-angiogenic growth
factor was increased during the relapse phase of EAE.
Cervical, thoracic and lumbar areas of the spinal cord
isolated from naive and EAE rats following PBS perfu-
sion (n = 5/group) were measured using a VEGF specific
ELISA. In both the cervical and lumbar areas of the
Table 3 Increased blood vessels during EAE
CD31 Collagen IV
naive EAE naive EAE
Lumbar WM 3.1 ± 0.1* 7.7 ± 1.2
† 2.8 ± 0.5** 8.7 ± 1.2
GM 6.7 ± 0.4 ** 13.0 ± 1.4 8.8 ± 1.6** 16 ± 1.5
Thoracic WM 2.9 ± 0.2** 5.9 ± 0.6 3.1 ± 0.2** 6.9 ± 0.6
GM 6.5 ± 0.7** 13 ± 1.2 9.2 ± 1.3* 17 ± 1.8
* p < 0.05 compared to EAE
**p < 0.01 compared to EAE
†Number of vessels counted using a 40× microscope objective
Figure 1 There is an increase in small blood vessels in the relapse phase of EAE. Vascular casting shows the vascular pattern of the lumbar
spinal cord in the normal rat (A). During acute EAE (B) there is no significant increase in blood vessel numbers. However, in the relapse phase (C) there
is an increase of blood vessel numbers, which shows increased tortuosity compared to healthy rats. Quantification using μCT demonstrates that in the
thoracic region of the spinal cord during EAE relapse there is no significant increase in blood vessel numbers (D). In contrast, in the lumbar region
versus the thoracic region, there is a significant increase in small diameter vessels (all vessels smaller than 24 μm) Student T test (p = 0.011) (E).
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VEGF levels compared to the naïve rats (Figure 4). In
the thoracic spinal cord the EAE rats had a lower VEGF
level but it did not reach significance.
To investigate this decrease, we performed immunohis-
tochemistry for VEGF at all stages of EAE. We found
that during the acute and relapse phases of EAE there
were VEGF immunopositive cells in the perivascular
inflammatory infiltrate (Figure 5). Additionally, VEGF
positive neuronal cell bodies were found throughout the
spinal cord in both naive rats and during acute EAE.
During the relapse phase of EAE, there were less VEGF
immunopositive neurons (Figure 5B). This decrease in
VEGF positivity in the neurons is likely responsible for
the observed decrease in VEGF measured by ELISA, even
in the presence of VEGF positive inflammatory infiltrates.
Other mediators of angiogenesis in the brain during
disease include Tie-2 (Tek), VEGFR2 (Flk-1) and
meteorin. As these mediators have not been previously
characterized in EAE, their expression was examined
during all phases of disease. Meteorin is a recently
described molecule that is secreted by astrocytes in vitro
to attenuate angiogenesis and is located on astrocyte
endfeet in the normal brain [31]. In agreement with pre-
vious reports, we found meteorin localized to the
abluminal side of blood vessels (Figure 6). During the
r e l a p s ep h a s eo fE A Ew ef o u n dad i s r u p t e de x p r e s s i o n
of meteorin immunoreactivity along some inflamed
blood vessels. Spinal cord tissue harvested from acute
phase rats had occasional VEGFR2 positive blood ves-
sels, the expression of which did not change during EAE
(data not shown). We did not detect expression of
VEGFR1 or Tie2 by endothelial cells or other cells dur-
i n ga n yo ft h ep h a s e so fE A E .T h i sm a yb ed u et ot h e
insensitivity of the antibodies available for these antigens
in rats (data not shown).
Angiogenesis mediators are changed in multiple sclerosis
lesions
To observe whether angiogenesis is a component of MS,
we next examined active chronic MS lesions for changes
in angiogenic proteins. Glial cells in the rim of the
active lesion expressed VEGF (Figure 7A), whilst in nor-
mal subjects VEGF expression was not detected by
immunohistochemistry (Figure 7B). Many glial cells in
the rim of the active chronic lesion and some blood ves-
sels expressed VEGFR2 (Figure 7C, D). There was mini-
mal expression of VEGFR2 in white matter from control
subjects (Figure 7E). The angiogenic mediator, VEGFR1
(Flt-1) was detected on the majority of blood vessels in
the control subjects (Figure 7F) and in the normal
appearing white matter of MS subjects (not shown).
Blood vessels surrounded by perivascular infiltrates (Fig-
ure 7G) or in central areas of the demyelinated lesion
(Figure 7H) expressed less VEGFR1 in greater than 70%
of the MS subjects, as compared to those found in con-
trol brains. Tie2 was found on the majority of blood
vessels in both control white matter and throughout the
MS lesions (data not shown). There was no staining for
the Tie2 ligand angiopoietin-2, in either the control
white matter or MS lesions. Meteorin was found to be
expressed on some blood vessels in both control white
matter and in some MS subjects but there was no clear
change in expression in relation to MS lesion location
(data not shown).
Discussion
These data demonstrate that angiogenesis occurs during
EAE similar to that seen in other chronic inflammatory
diseases [32]. Previously angiogenesis was suggested by
increased plasma VEGF levels [22] and increased blood
vessel density in EAE [18,19]. Using vascular casting and
histology, we demonstrate an increase in blood vessel
density specifically during the relapse phase, but not
during the acute phase of EAE. In particular, we
observed that angiogenesis prevailed in the lumbar
region which most likely is in line with the ascending
paralysis that is observed with this model. However, a
more detailed analysis of the angiogenic potential of
specific infiltrating immune cell subtypes and the
response by neural cells needs to be performed.
Figure 2 Increased blood vessel density as seen with collagen
IV and CD31 immunohistochemistry. Representative collagen type
IV and CD31 immunohistochemical stains from the lumbar spinal
cord region. In the white matter of the naïve rats, collagen IV and
CD31 blood vessels are found. In the EAE rats during the relapse
phase there are more collagen IV positive blood vessels seen in the
inflamed white matter. CD31 immunohistochemistry shows a similar
increase in blood vessel density. Interestingly in some of the blood
vessels, the CD31 staining became much more diffuse (arrows) and
not as prominent as compared to the naïve rats.
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the different phases of EAE. Animals display neurological impairment during the acute phase and relapse, whereas they show almost complete
remission between the two episodes. The acute inflammatory phase ranges from 9 to 17 dpi, the remitting phase from 17 and 21 dpi and
relapse from 21 to 26 dpi. (B) Collagen IV immunohistochemistry and subsequent quantification shows a significant increase of blood vessels at
day 22 (relapse) in the lumbar spinal cord grey and white matter. There is little change in blood vessel numbers in either the thoracic or cervical
spinal cord, with the exception of a small increase in the thoracic white matter at day 22 post immunization. n = 5/rats timepoint mean ± S.D. °
p < 0.05 compared to day 13, * p < 0.05 compared to naive rats.
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a variety of mechanisms. Macrophages and T cells pro-
duce cytokines such as TNF, IL-8, TGF-b and MMP-9,
which are known angiogenic factors [33,34]. Further-
more macrophages can produce VEGF, the most potent
known inducer of angiogenesis [35,36]. As these same
cells and soluble factors are found in EAE and
MS lesions it is perhaps not surprising that angiogenesis
is occurring [37]. Indeed the main location of inflamma-
tion is the perivascular area of the CNS [5], which is
ideal for acting upon endothelial cells and smooth mus-
cle cells to induce angiogenesis. Our current data
demonstrates that new blood vessels are formed only
during the relapse phase of EAE. This suggests that the
vasculature does not respond quickly to neuroinflamma-
tion but must be acted upon in a more chronic manner.
Further experiments examining a more chronic EAE
model such as myelin oligodendrocyte glycoprotein
induced EAE in the DA rat model would address this
aspect. In addition the cellular infiltrate differs over
time, which may change the angiogenic milieu within
the CNS, thus the effects of the different inflammatory
subtypes on glia, neurons and the BBB should be exam-
ined. Lastly the difference between the lumbar and
Figure 4 EAE results in a significant decrease in spinal cord
VEGF. Spinal cords were harvested during the relapse phase of EAE,
divided into cervical, thoracic and lumbar areas, homogenized and
measured using a specific rat VEGF ELISA kit. There is a significant
decrease in VEGF in the cervical and lumbar areas in EAE rats
compared to naïve controls. * p < 0.05, **p < 0.01 n = 5 rats per
group
Figure 5 Inflammatory infiltrates express VEGF but neuronal expression is decreased during EAE relapse. In acute EAE some cells in the
inflammatory infiltrate (arrow) and spinal cord neurons (arrowheads) express VEGF (A). During EAE relapse there is a decrease in neuronal
expression of VEGF (arrowheads) but some infiltrating cells near blood vessels continue to express VEGF (arrows, B). Scale bar = 100 μm
Figure 6 Vascular meteorin expression is affected during EAE in
the lumbar spinal cord. Meteorin immunoreactivity is closely
associated with many blood vessels and appears to completely
surround blood vessels in naive rats (A, arrowhead). In addition there
are a few branched cells in the parenchyma expressing meteorin,
which resemble astrocytes (arrows, A). In relapsing EAE rats there are
breaks in the blood vessel (asterisks, B) associated meteorin in the
white matter of the lumbar spinal cord. scale bar 50 μm.
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differences in the physiology of these two anatomical
locations. Alternatively, the differences may be due to
the inflammation being more intense and/or chronic in
the lumbar. The vascular casting demonstrated that the
increase was seen in small blood vessels, whilst the lar-
ger vessel numbers remained stable. This finding is logi-
cal as it would be expected that the newly formed blood
vessels would be smaller. Our findings are somewhat
different to those recently reported by Roscoe and col-
leagues [19], as they found an increase in laminin posi-
tive blood vessels during the acute phase of EAE. This
could be due to a number of factors including species
differences (mouse vs. rat, current study) and method of
EAE induction (MOG35-55 plus pertussis toxin vs. spinal
cord homogenate, current study). Nonetheless, both stu-
dies reported an increase in blood vessels during EAE.
Therefore, using both histological examination and vas-
cular casting we have demonstrated that angiogenesis
occurs in EAE and thus may also be present in MS.
Angiogenesis in the adult brain is a complex interac-
tion of several pathways involving various different
receptors and signaling molecules [6,38]. Mueller et al.
recently published an extensive gene array analysis of
myelin oligodendrocyte protein induced EAE in the DA
rat [39]. Examination of this data set showed modula-
tion of several angiogenic factors including VEGF and
its receptors. Many of these same proteins are impli-
cated in angiogenesis found in tumours, stroke and epi-
l e p s y[ 1 4 - 1 6 ] .B a s e do nt h e s ed a t aw ee x a m i n e dV E G F ,
VEGFR1, VEGFR2, Tie-2, angiopoietin-1 and meteorin
in the current study. During the relapse phase of EAE
meteorin expression was discontinuous along some
blood vessels. Meteorin is located on astrocytic endfeet
and acts through thrombospondin-1/2 to promote vas-
culature maturation [30]. As far as we are aware, this is
the first report that meteorin expression is changed dur-
ing neuroinflammation. In human MS lesions, there was
an increase of VEGFR2 expression by both glial cells in
the rim of the lesion and blood vessels. There was
decreased VEGFR1 expression by blood vessels that had
a perivascular cuff of inflammation and those located in
demyelinated areas. As previously reported, Tie-2 was
present on CNS blood vessels but we did not find angio-
poietin-1 expressed. These data demonstrate that a pro-
angiogenic environment is present in the inflamed brain.
The expression of VEGF during EAE is controversial,
with both increased [19,20] and decreased [29] expres-
sion reported. We found a decreased level of VEGF as
measured by ELISA. Immunohistochemistry demon-
strated that neuronal expression of VEGF was present
during acute EAE, whilst during the relapse phase, neu-
ronal VEGF was decreased. Our data suggest that the
contradictory results reported are due to a number of
differences. Both Tham et al [29] and Proescholdt et al
[20] used guinea pig MBP peptide induced EAE in
Lewis rats. Firstly, the timing of the tissue analysis is
important, as we have found that VEGF is expressed by
neurons and inflammatory infiltrates in acute EAE but
neurons decrease expression during relapse. Secondly,
the spinal cord area examined will influence the results.
Proescholdt and colleagues examined the white matter,
whilst Tham and colleagues examined neurons in the
grey matter and lumbar spinal cord homogenate. As
we found VEGF to be expressed by infiltrates but
decreased in neurons after the acute phase of disease,
this may explain some of the differences. Lastly, there
are technical differences due to different antibodies
used, immunohistochemical protocols and detection
Figure 7 Increased VEGF and VEGFR2 but decreased VEGFR1 in
MS lesions. Glial cells expressed VEGF in the rim of chronic
demyelinated lesions in > 70% of the samples (asterisks, A) but
there was no expression in the white matter of any of 5 control
subjects (B). Glial cells (asterisks, C) and blood vessels (D) in areas of
demyelination located in the center of the lesion and the rim
expressed VEGFR2 in > 70% of samples, but there was minimal
staining in all the normal subjects (E, arrow points to blood vessel).
Blood vessels in all normal subjects expressed VEGFR1 (arrow, F) but
there was a reduction in blood vessels surrounded by inflammation
(arrow, G) or in the central area of the lesion (arrow, H) in the
majority of subjects with MS. scale bars = 20 μm.
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Nevertheless, our data demonstrates that VEGF is
m o d u l a t e dd u r i n gE A Ea n dm a yh a v ear o l ei ni t s
pathophysiology. Further experiments using double
immunohistochemistry and flow cytometry should be
performed to examine the production of angiogenic
factors by the different inflammatory cells (Th1, Th17,
Tregs, macrophages ect.) and determine changes over
t h ec o u r s eo fE A E .
The downregulation of VEGF in the neurons during
relapse could be due to a number of mechanisms. As
VEGF has a role in neuroprotection [40], its decrease by
neurons may be involved in neural damage seen in the
paralytic episodes following the acute phase. McCloskey
and colleagues have demonstrated a decrease in neuro-
nal VEGF following excitation induced by convulsions
[41], therefore perhaps a similar mechanism exists dur-
ing EAE. Alternatively, since it has been demonstrated
that VEGF-A can disrupt the BBB, the decrease in neu-
ronal VEGF may act as a counter regulatory mechanism
to balance the increased VEGF due to the inflammatory
infiltrates [42]. Lastly, the inflammation may supply exo-
genous VEGF to the neurons, thus allowing neurons to
reduce endogenous VEGF production.
In the MS lesions, glial cells in the active rim of the
lesion expressed VEGF, similar to that reported by
others [20,43]. Therefore, both the receptor VEGFR2
and its ligand VEGF are expressed in the MS lesion.
The expression of VEGFR2 by endothelial cells likely
has an important role in the formation of new blood
vessels, while the role on astrocytes is less clear. In
humans there have been reports of astrocytoma expres-
sion of VEGFR2 [44] therefore a similar pathway may
be activated in MS lesions to promote angiogenesis and
glial survival or activation.
Overall, these data demonstrate that angiogenesis is
increased in EAE and that a pro-angiogenic environ-
ment exists in MS lesions. Angiogenesis is increased
during the relapse phase of EAE and therefore may be
central to the propagation of the chronic immune
response seen in MS.
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